High Expression of CLDN 18.2 is Associated with Poor Disease-Free Survival of HER-2 Positive Gastric Cancer
Tongxin Zhang,Zilong He,Yankui Liu,Linfang Jin,Teng Wang
DOI: https://doi.org/10.2147/ijgm.s453883
IF: 2.145
2024-04-30
International Journal of General Medicine
Abstract:Tongxin Zhang, 1, 2 Zilong He, 1, 2 Yankui Liu, 3 Linfang Jin, 4 Teng Wang 1, 2 1 Department of Oncology, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, 214122, People's Republic of China; 2 Wuxi Medical College, Jiangnan University, Wuxi, Jiangsu, 214122, People's Republic of China; 3 Department of Pathology, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, 214122, People's Republic of China; 4 Department of Pathology, Wuxi No. 9 People's Hospital, Wuxi, Jiangsu, 214062, People's Republic of China Correspondence: Teng Wang, Department of Oncology, Affiliated Hospital of Jiangnan University, 1000 Hefeng Road, Binhu District, Wuxi, Jiangsu Province, 214000, People's Republic of China, Tel +8618861530279, Email Background: Anti-claudin (CLDN) 18.2 therapy has been proven to be effective in treating advanced gastric cancer with negative human epidermal growth factor receptor 2 (HER-2). This study purposed to investigate the relationship of CLDN 18.2 expression with prognosis of HER-2-positive gastric cancer patients. Objective: To investigate the expression of claudin (CLDN) 18.2 in Human epidermal growth factor receptor 2 (HER-2) positive gastric cancer patients after radical resection and its relationship with gastric cancer prognosis. Methods: A total of 55 postoperative HER-2-positive gastric cancer patients were included in this study. CLDN 18.2 protein was detected by immunohistochemistry, and detailed clinical and pathological information was collected. Factors considered potentially important in the univariate analysis were included in the multivariate analysis, which involved COX regression to find the independent prognostic factors affecting disease-free survival (DFS). Results: Immunohistochemistry showed that different levels of CLDN 18.2 protein were expressed in HER-2 positive gastric cancer tissues, and the Chi-square analysis showed that the expression level of CLDN 18.2 was significantly correlated with the lymph node stage. Higher expression levels of CLDN 18.2 were found in patients with lymph node positivity and were associated with poor prognosis in HER-2-positive gastric cancer patients. Gastric cancer patients with low and high expressions of CLDN 18.2 had postoperative median DFS of 38.5 months (95% confidence interval (CI) 28.8– 48.2 months) and 12.1 months (95% CI, 11.7– 41.0 months), respectively. Conclusion: High expression of CLDN 18.2 in HER-2 positive gastric cancer is associated with poor prognosis, and the optimal treatment mode for this population is worth exploring after the approval of anti-CLDN 18.2 drugs. Keywords: gastric cancer, HER2, claudin 18.2, prognosis Gastric cancer is one of the most common malignant tumors worldwide, 1 with nearly 50% of the global cases occurring in China. 2 Drug therapy, including chemotherapy, target therapy, and immunotherapy, is the key treatment for gastric cancer, which can significantly improve overall survival. Combining targeted therapy with chemotherapy and immunotherapy can further improve their efficacy. Human epidermal growth factor receptor 2 (HER-2) was the first therapeutic target to be confirmed for gastric cancer, and several clinical trials have confirmed the efficacy of anti-HER-2 therapy in treating gastric cancer. 3–5 Tight junctions are usually located at the tip of epithelial cells and have the function of intercellular adhesion. Recently, the dysfunction and alteration of tight junction proteins in a variety of cancer cells has attracted attention. Tight junctions are mainly composed of occludin and claudin (CLDN) proteins. CLDNs are transmembrane proteins involved in maintaining intercellular integrity and regulating paracellular ion transport. 6 Currently, there are 27 members of the CLDN protein family, of which CLDN 1 7 and CLDN 10 8 have been shown to have prognostic value in colon cancer and hepatocellular carcinoma, respectively, and CLDN 18 9 has prognostic value in gastric cancer. In 2008, a study identified the splice variant 2 of CLDN 18, CLDN 18.2, as a highly selective biomarker that is limited in normal tissues but highly expressed in the initiation and progression of various primary malignancies 10 , and in addition, CLDN18.2 is exposed on the cell surface in cancer cells, which enables its binding to monoclonal antibodies. More and more studies have shown that Claudin 18.2 can be used as a new molecular biomarker and immunotherapy for cancer. 11 However, CLDN 18.2 has recently been identified as a new therapeutic target for gastric cancer. 12,13 Combining monoc -Abstract Truncated-
medicine, general & internal